Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic obstructive ...

Firstly, as per the report of the third quarter of 2024, significant financial growth was seen as the net sales reported were $5.6 million, largely due to product sales of Ohtuvayre. Secondly, ...

Firstly, as per the report of the third quarter of 2024, significant financial growth was seen as the net sales reported were $5.6 million, largely due to product sales of Ohtuvayre. Secondly, ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions ...

Likewise, Verona Pharma (VRNA) proved a strong contributor after it released strong quarterly earnings highlighting the strong launch of Ohtuvayre, its chronic obstructive pulmonary disease (COPD ...